A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study

A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study Ongoing） is a phase 2, interventional study registered as NCT07609251 by Sinocelltech Ltd., with a registry enrolment figure of 90 participants, started 2026-05 and due to reach its primary completion in 2028-10. Interventions recorded: SCTB41; docetaxel. Conditions listed: NSCLC (Advanced Non-small Cell Lung Cancer). Primary outcome: Frequency of adverse events (AEs). Lung eligibility wording from the registry: "Histologically or cytologically confirmed locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) that is not amenable to complete surgical resection and cannot receive curative concurrent/sequential chemoradiotherapy;". Sites: China. No results are recorded here; the registry entry is the source.